Trending Now
Is Elon Musk done selling TSLA stock to cover Twitter sale
Tesla Inc (TSLA) stock is currently trading at $191.30 down over 15% in the past 5 trading days. So what caused the...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Clinches $450 Million Deal From The US...
The Trump administration awarded a $450 million contract under ‘Operation Warp Speed’ to Regeneron Pharmaceuticals Inc (NASDAQ:REGN)(RPC) to develop and quickly distribute the antibody...
MAKE IT MODERN
LATEST REVIEWS
Earnings Spotlight: Microsoft’s Anticipated Quarterly Performance and Strategic Moves (MSFT)
Microsoft (MSFT) is poised to unveil its earnings after the market closes Tuesday, with a management conference call scheduled for 5:30 p.m.
MAKE IT MODERN
PERFORMANCE TRAINING
Adptimmune Therapeutics Plc (NASDAQ: ADAP) Releases Encouraging Data From SURPASS Study in Multiple Tumors
Adptimmune Therapeutics Plc (NASDAQ: ADAP) has announced its latest data from the first phase SURPASS study in multiple solid tumors. The data will be...
A Look at Top Recession-Proof Stocks in the Alcohol Space (DEO, KEGS, STZ, BF.B,...
As noted by major Wall Street houses of late, the odds of a US (and possibly global) recession have jumped over recent...
OncoCyte Corp (NYSEAMERICAN:OCX) and the Guardian Research Network® Collaborate to Establish an Integrated Platform...
Cancer is a leading cause of death in the United States. Victims and their families, employers, and insurance companies spend over 150 billion dollars...
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Commences Phase 2A Study Evaluating PH94B in Anxiety Treatment
VistaGen Therapeutics Inc. (NASDAQ: VTGN) has announced the commencement of phase 2A clinical study to assess safety, tolerability, and efficacy of PH94B as a...
Investing in Disruptive Technology: The Healthcare Opportunity (USAQ, PLTR, EXAS, MDT, VEEV, CERN)
No industry is safe from the disruptive encroachment of technological advances. None.
And those advances are happening at a...
























































